Highlights

  • Cogstate (ASX:CGS) reported FY26 sales contracts executed of US$89.0 million.
  • FY26 revenue reached approximately US$60.9 million, with net profit after tax of approximately US$11.9 million.
  • Contracted future revenue stood at US$118.5 million at 30 June 2026.
  • The company announced an XPRIZE Healthspan cognitive measurement collaboration in August 2026.

Cogstate Limited (ASX:CGS) develops digital cognitive assessments and provides clinical trial endpoint data quality services for drug research and healthcare applications. On 22 October 2026, Cogstate (ASX:CGS) was quoted at AUD 3.56, down 0.56% for the trading session. Its FY26 financial reporting and recent cognitive measurement collaboration place attention on contract delivery, research services and the progression of revenue already secured for subsequent periods.

Company Business

Cogstate (ASX:CGS) supplies computerized tests designed to measure memory, attention and other aspects of cognition. Its clinical trial work includes digital assessment, remote testing, scientific consulting, rater training and centralized monitoring of assessment quality. Sponsors use these services to evaluate cognitive endpoints in neurological, psychiatric and other therapeutic research. Customers include biopharmaceutical companies, research institutions and healthcare providers operating internationally.

The business also offers healthcare-focused screening tools, including Cognigram for healthcare professionals and the Lila memory application for individual monitoring. These are distinct from the services provided to pharmaceutical clinical trials. The commercial mix matters because clinical trial revenue depends on sponsor projects, their duration and the timing of assessment work, while healthcare tools operate through separate customer channels.

Recent Development

In July 2026, Cogstate (ASX:CGS) reported net sales contracts executed of US$21.9 million during the June quarter. Contracts executed across FY26 totalled US$89.0 million, compared with US$41.3 million in FY25, representing an increase of approximately 116%. Contract values are not equivalent to revenue recognized during the period: activity is delivered and billed across the agreed project schedules.

At 30 June 2026, total contracted future revenue was US$118.5 million, approximately 32% above the preceding year-end balance. Of that amount, US$48.3 million was expected to be recognized during FY27, including US$46.1 million in the Clinical Trials business. These amounts provide a contracted work base but remain subject to clinical trial timing, sponsor decisions and delivery arrangements.

In August 2026, the company announced its selection as a cognitive measurement partner for the XPRIZE Healthspan competition. Its role involves measures of cognitive performance for participating teams. The collaboration relates to assessment capability and should not be interpreted as a quantified revenue contribution without a disclosed contract value. Cogstate also continued communicating developments in cognitive endpoints and clinical research methodology during 2026.

Financial Performance and Sector Context

For FY26, Cogstate (ASX:CGS) reported revenue of approximately US$60.9 million, an increase of about 15% year on year. Net profit after tax was approximately US$11.9 million, up about 17%. Gross profit was approximately US$35.4 million, corresponding to a margin near 58%, while profit before tax was approximately US$16.1 million. Figures in this section are denominated in US dollars, consistent with the company’s financial reporting.

The company reported cash of approximately US$34.8 million at the end of FY26 and no debt. Its board declared a fully franked final dividend of AUD 0.04 per ordinary share. The June 2026 half-year financial outcome followed a first half in which revenue was US$26.9 million and EBITDA was US$6.5 million. This difference illustrates why clinical trial timing and the revenue recognition schedule are material when comparing halves.

The operating environment includes trials in Alzheimer’s disease, psychiatric disorders and other central nervous system conditions. Cogstate provides measurement and data quality services rather than the experimental medicines themselves. Demand for its work is therefore linked to research program activity, trial design, sponsors’ budgets and the availability of clinical study sites. Its contract order book should be considered alongside the cost of delivering studies.

Risks to Consider

Cogstate (ASX:CGS) faces project timing and cancellation risks where sponsors modify, delay or discontinue trials. Revenue recognition may shift between reporting periods even when a contract has been executed. Other considerations include dependence on specialized scientific personnel, software development costs, data privacy requirements and competition for clinical research contracts. International contracts may also create currency exposure and regulatory compliance obligations.

What to Watch Next

Key reported indicators for FY27 include new clinical trial sales contracts, the conversion of the US$48.3 million FY27 contracted revenue position into recognized revenue, changes in gross and EBITDA margins, and subsequent cash balances. Quarterly contract updates will also clarify whether sales activity is concentrated in particular therapeutic areas or spread across multiple indications. Updates on the healthcare testing products and collaborative research programs provide additional operational context.

Key Insights

Cogstate (ASX:CGS) entered FY27 after reporting higher FY26 revenue and profit, with an expanded contracted future revenue position. Its operating profile combines digital cognitive testing, trial assessment quality services and clinical healthcare tools. The principal measurable developments remain contract execution, project delivery, margins, cash generation and the progress of disclosed collaborations. These factors provide a framework for interpreting later company financial and operational announcements.